undamentalytics Newsletter
Sign in

10x Genomics, Inc. cash flow statement

In fiscal 2025, 10x Genomics, Inc.'s operations generated $136m of cash; it spent $5.9m on capital projects, leaving free cash flow of $130m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−11−7635−218−21−34−157136127
Depreciation and amortisation44714212536363640
Stock-based pay2313499613716714110999
Capital spending464337101132491266
Free cash flow−14−83−8−255−123−165−64−6130121
Free cash flow after stock pay−16−85−21−303−219−302−231−1462123
Share buybacks0—————————
Shares issued—041148200————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AZTA vs TXGTXG vs VCYTNEO vs TXGRGEN vs TXG

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 10x Genomics, Inc.